Mitochondrial carrier deficiency associated with shuttle disturbances (Homo sapiens)

From WikiPathways

Revision as of 15:50, 21 December 2024 by Egonw (Talk | contribs)
(diff) ←Older revision | Current revision (diff) | Newer revision→ (diff)
Jump to: navigation, search


Description

Amino acid metabolism in triple-negative breast cancer cells. The glutamine, serine and glycine metabolic pathways are significantly upregulated. The upregulated expression of key genes within the glutamine, serine and glycine metabolic pathways have also been observed in triple-negative breast cancer cells

Try the New WikiPathways

View approved pathways at the new wikipathways.org.

Quality Tags

Ontology Terms

 

Bibliography

  1. Bhutia YD, Babu E, Ramachandran S, Ganapathy V; ''Amino Acid transporters in cancer and their relevance to "glutamine addiction": novel targets for the design of a new class of anticancer drugs.''; Cancer Res, 2015 PubMed Europe PMC Scholia
  2. Kung HN, Marks JR, Chi JT; ''Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia.''; PLoS Genet, 2011 PubMed Europe PMC Scholia
  3. Kim SK, Jung WH, Koo JS; ''Differential expression of enzymes associated with serine/glycine metabolism in different breast cancer subtypes.''; PLoS One, 2014 PubMed Europe PMC Scholia
  4. Christiaan F. Labuschagne, Niels J.F. van den Broek, Gillian M. Mackay, Karen H. Vousden, Oliver D.K. Maddocks; ''Serine, but Not Glycine, Supports One-Carbon Metabolism and Proliferation of Cancer Cells''; https://doi.org/10.1016/j.celrep.2014.04.045, 2014 DOI Scholia
  5. Wang Z, Jiang Q, Dong C; ''Metabolic reprogramming in triple-negative breast cancer.''; Cancer Biol Med, 2020 PubMed Europe PMC Scholia

History

View all...
CompareRevisionActionTimeUserComment
136173view15:50, 21 December 2024EgonwRemoved template comments
136142view16:37, 19 December 2024DaanvanbeekRhea's added, check GLUD1, can go both directoins and NAD or NADP
136139view16:25, 19 December 2024DaanvanbeekAdded Rhea identifiers
136134view15:47, 19 December 2024Daanvanbeeklayout change
136133view15:47, 19 December 2024DaanvanbeekLayout change
136132view15:46, 19 December 2024DaanvanbeekAdded GOT2 disease
136131view15:43, 19 December 2024DaanvanbeekAdded diseases
136126view15:08, 19 December 2024DaanvanbeekNew pathway

External references

DataNodes

View all...
NameTypeDatabase referenceComment
2-oxoglutarateMetaboliteHMDB0000208 (HMDB)
GLUD1GeneProductENSG00000148672 (Ensembl)
GOT2GeneProductENSG00000125166 (Ensembl)
H+MetaboliteCHEBI:24636 (ChEBI)
Oxidative phosphorylationPathwayWP111 (WikiPathways)
SLC25A12GeneProductENSG00000115840 (Ensembl) Mitochondrial membrane transporter
SLC25A13GeneProductENSG00000004864 (Ensembl) Mitochondrial membrane transporter
SLC25A22GeneProductENSG00000177542 (Ensembl) Mitochondrial membrane transporter
TCA CyclePathwayWP78 (WikiPathways)
aspartateMetaboliteCHEBI:29995 (ChEBI)
glutamateMetabolite33032 (PubChem-compound)
oxaloacetateMetaboliteHMDB0000223 (HMDB)

Annotated Interactions

View all...
SourceTargetTypeDatabase referenceComment
2-oxoglutaratemim-conversion21827 (Rhea)
H+70958 (Rhea)
H+Arrow70958 (Rhea)
aspartate70786 (Rhea)
aspartateArrow70786 (Rhea)
aspartateoxaloacetatemim-conversion21827 (Rhea)
glutamate2-oxoglutaratemim-conversion11613 (Rhea)
  • Maybe also reversed reaction possible through GLUD1, GLUD1 can use both NAD(H) and NADP(H) which are different RHEA entries
  • Type your comment here
glutamateArrow70786 (Rhea)
glutamateglutamatemim-conversion70958 (Rhea)
glutamatemim-conversion21827 (Rhea)
Retrieved from "https://classic.wikipathways.org/index.php/Pathway:WP5507"
Personal tools